ResMed (RMD) Stock Price, News & Analysis

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RMD shares.
View RMD analyst ratings or view top-rated stocks.

10 Wall Street analysts have issued 12 month price targets for ResMed's shares. Their RMD share price targets range from $165.00 to $230.00. On average, they predict the company's stock price to reach $199.20 in the next twelve months. This suggests a possible upside of 14.6% from the stock's current price.
View analysts price targets for RMD or view top-rated stocks among Wall Street analysts.

ResMed's stock was trading at $172.02 at the beginning of 2024. Since then, RMD shares have increased by 1.1% and is now trading at $173.86.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our RMD earnings forecast.

ResMed will be holding an earnings conference call on Thursday, April 25th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415 with passcode "13745785".

ResMed Inc. (NYSE:RMD) issued its quarterly earnings data on Wednesday, January, 24th. The medical equipment provider reported $1.88 earnings per share for the quarter, beating the consensus estimate of $1.81 by $0.07. The medical equipment provider had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.15 billion. ResMed had a net margin of 19.77% and a trailing twelve-month return on equity of 23.86%. The business's revenue for the quarter was up 12.5% compared to the same quarter last year. During the same period last year, the company posted $1.66 EPS.
Read the conference call transcript.

ResMed declared a quarterly dividend on Wednesday, January 24th. Stockholders of record on Thursday, February 8th will be given a dividend of $0.48 per share on Thursday, March 14th. This represents a $1.92 dividend on an annualized basis and a dividend yield of 1.10%. The ex-dividend date is Wednesday, February 7th.
Read our dividend analysis for RMD.

ResMed (NYSE:RMD) pays an annual dividend of $1.92 per share and currently has a dividend yield of 1.04%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 31.74%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RMD will have a dividend payout ratio of 23.30% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RMD.

ETFs with the largest weight of ResMed (NYSE:RMD) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Fidelity Digital Health ETF (FDHT), Emerge EMPWR Sustainable Select Growth Equity ETF (EMGC), iShares U.S. Medical Devices ETF (IHI), First Trust Indxx Medical Devices ETF (MDEV), Capital Group Global Growth Equity ETF (CGGO), SPDR S&P Health Care Equipment ETF (XHE) and Invesco S&P 500 Equal Weight Health Care ETF (RYH).

284 employees have rated ResMed Chief Executive Officer Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among the company's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

ResMed's stock is owned by many different retail and institutional investors. Top institutional investors include Congress Asset Management Co. MA (0.40%), Los Angeles Capital Management LLC (0.34%), Confluence Investment Management LLC (0.09%), ST Germain D J Co. Inc. (0.07%), Massmutual Trust Co. FSB ADV (0.04%) and Addenda Capital Inc. (0.03%). Insiders that own company stock include Brett Sandercock, Carol Burt, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Karen Drexler, Kaushik Ghoshal, Lucile Blaise, Michael J Farrell, Michael J Rider, Peter C Farrell, Rajwant Sodhi and Robert Andrew Douglas.
View institutional ownership trends.

Shares of RMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.